The Pharma Data

JUNE 24, 2025

We look forward to this strategic alliance continuing to expand the frontiers of cutting-edge science and translating groundbreaking discoveries into transformative treatments for patients.” Since 2009, Bayer has actively cultivated academic partnerships with major Chinese institutions, including Peking University (since 2014).

Pharma R&D

Drug Target Review

JULY 29, 2025

Kyle notes that “clinical trials face costly delays, inefficient resource allocation, and even standstill or stalling of trials, ultimately resulting in the failure to bring crucial treatments to market.” Jennifer has been a licensed CPA (California) since July 2014. Available from: [link]

Clinical Trials

New Drug Approvals

JUNE 25, 2025

Consequently, a GK activator may provide therapeutic treatment for NIDDM and associated complications, inter alia, hyperglycemia, dyslipidemia, insulin resistance syndrome, hyperinsulinemia, hypertension, and obesity. Frequent use of these drugs may lead to weight gain and may induce edema and anemia. (E) For example, U.S.

Small Molecule

New Drug Approvals

JULY 8, 2025

It is being investigated as a potential treatment for various herpes infections, including those resistant to traditional antivirals like acyclovir. Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).

Virus

Drug Patent Watch

JANUARY 14, 2025

The stakes are higher than ever, with billions of dollars and potentially life-saving treatments on the line. The collapsed talks between Pfizer and AstraZeneca in 2014 highlight the need for flexibility, realistic valuations, and a deep understanding of regulatory hurdles in cross-border deals.

Pharmaceuticals

FDA Law Blog: Biosimilars

APRIL 7, 2025

Specifically, the Librela ads show before and after treatment with no risk information, thereby making efficacy claims without fair balance, particularly because the Important Safety Information is not visible unless the viewer clicks on the more button to expand the text box.

Vaccine

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 25, 2024

Contrary to worries that syringe services programs (SSPs) will encourage or promote drug use, evidence shows that they more often do the opposite, linking people with addiction to effective treatment and even helping prevent overdose deaths. Unfortunately, prejudices against harm-reduction continue to impede the reach of SSPs.

Drugs

FDA Law Blog: Drug Discovery

JANUARY 12, 2025

Since that time, it was formalized in FDA regulations (21 CFR 314 Subpart H) in 1992, codified in the Food, Drug, & Cosmetic Act by FDAMA (21 USC 356(c)) in 1997, revised by FDASIA in 2012, and described in guidance, most importantly, in the 2014 Expedited Programs for Serious Conditions Drugs and Biologics (2014 Guidance).

FDA

The Pharma Data

JUNE 26, 2025

Incyte’s track record for discovering innovative treatments for complex problems in human health is outstanding. My priority is to build upon our exceptional R&D and commercial capabilities to accelerate new product flow, drive sustainable growth and create value for all stakeholders.

Production

BioPharma Drive: Drug Pricing

AUGUST 11, 2025

GoodRx research shows an average 39% list price increase for all prescription medications since 2014, and in 2024 Americans paid $61 billion in OOP costs for their prescription medications. Formulary designs continuously evolve and formulary exclusions and other restrictions increase each year, increasing patients’ cost burden.

New Drug Approvals

JULY 18, 2025

3] It was discovered for the treatment of hepatitis C [4] and has since been investigated for use against other viral diseases such as AIDS and COVID-19 , [2] [5] for which it was granted conditional approval in China. [6] It was approved in China in 2021 as a first-in-class treatment for human immunodeficiency virus (HIV).

RNA

New Drug Approvals

JULY 21, 2025

Hetrombopag olamine (6), an oral nonpeptide thrombopoietin receptor (TpoR)agonistdevelopedby JiangsuHengruiPharmaceutical, was approved in China in June2021 for treatment of adult patients with chronic primary immune thrombocytopenia (ITP) and severe aplastic anemiawhohave not responded well to other treatments.46Hetrombopag,

Small Molecule

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment

addgene Blog

NOVEMBER 2, 2023

In 2014, we wrote a blog post on CRISPR’s potential for correcting monogenetic diseases. Now, almost 10 years later, CRISPR’s potential for treatment is no longer an accurate descriptor; progress in clinical therapy is more fitting, so it is time to update our post.

Therapies

Broad Institute

NOVEMBER 7, 2023

While RA therapies targeted to specific inflammatory pathways have emerged, only some patients’ symptoms improve with treatment, emphasizing the need for multiple treatment approaches tailored to different disease subtypes.

Treatment

SCIENMAG: Medicine & Health

AUGUST 15, 2023

By utilizing whole exome sequencing on tumor tissues and their non-tumor counterparts obtained from thirty SA-CRC patients diagnosed at Changzheng Hospital from 2014 to […]

Research

Broad Institute

OCTOBER 3, 2024

Largest-ever genetic study of epilepsy finds possible therapeutic targets By Ari Navetta October 3, 2024 Breadcrumb Home Largest-ever genetic study of epilepsy finds possible therapeutic targets Scientists have uncovered new genetic links to different types of epilepsy, which could lead to more tailored treatments.

DNA

Common Sense for Drug Policy Blog

OCTOBER 7, 2023

2014 ; Joudrey et al., 2014 ; Joudrey et al., Given that the median duration of prison stay was only 16 days, excess risk of infection-related hospitalization after release may also reflect people seeking treatment outside prison for infections that initially developed before or during incarceration ( Lloyd et al., 2023.104218.

Hospitals

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies

Drug Target Review

AUGUST 24, 2023

We will explore how GDF-15 impacts the tumour microenvironment and hinders the infiltration of T cells into the tumour, as well as the implications of neutralising GDF-15 to reverse its inhibitory effects and sensitise tumours to anti-PD-1 treatment. T-cell infiltration is a prerequisite for responses to checkpoint inhibitors.

Treatment

Drug Target Review

JANUARY 8, 2024

Our lead program utilises OSK for the treatment of age-related optic neuropathies. acquired by Teva Pharmaceuticals in 2014. What evidence is there that we can reverse aging with drugs? Before that, he served as president and CEO of AgeneBio, Inc.,

Science

Drug Target Review

OCTOBER 17, 2023

To improve its treatment, early diagnosis and appropriate therapeutic strategies are very important. Metabolic changes such as increased arginine levels could serve as biomarkers for detecting cancer at an early stage, which is essential for successful cancer treatment and patient survival. This research was published in Cell.

Regulations

Common Sense for Drug Policy Blog

DECEMBER 20, 2023

Juvenile Drug Courts "As shown in Figure 13, a total of 420 JDCs were operating across the United States in 2014. Overall, between 2014 and 2021, the number of JDCs in the United States decreased by 30%." Data Digest Issue 2: Treatment Court Counts. This number decreased to 305 by 2019 and again to 296 by the end of 2021.

Drugs

Drug Target Review

NOVEMBER 17, 2023

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies

The Pharma Data

DECEMBER 30, 2020

(NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive results from the long-term, open-label Phase 3 MOVEMENT trial of AXS-07, Axsome’s novel, oral, multi-mechanistic investigational medicine in the acute treatment of migraine.

Trials

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Prior to the founding of IN8bio, from 2014 to 2017, Mr Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Mr Ho has worked in the biotechnology industry for almost 20 years.

Therapies

NIH Director's Blog: Drug Development

SEPTEMBER 26, 2019

As a second and more challenging test, the researchers reconfigured the BOC by placing a multi-drug resistant vulva cancer cell line in one chamber and, in another, a breast cancer cell line that responded to drug treatment. Both tamoxifen alone and the combination treatment showed some off-target effects on heart cells.

Drugs

The Pharma Data

NOVEMBER 30, 2020

30, 2020 — For colon cancer patients, Medicaid expansion is associated with earlier diagnosis, enhanced access to treatment, and improved surgical care, according to a study published online Nov. Patients in nonexpansion states were compared to those in expansion states in January 2014. MONDAY, Nov. Hoehn, M.D., © 2020 HealthDay.

Treatment

Eye on FDA

JUNE 14, 2023

The numbers plummet in 2014 until the record low last year of only 4 letters. The latest letter was issued for a website that promoted a treatment for hypercortisolemia in patients with Cushings Disease. That is the record high for a single year since that time and means that they were coming out a rate of over 12 a month on average.

FDA

The Pharma Data

AUGUST 12, 2020

The first trial compared Opdivo combined with chemotherapy to chemotherapy alone as a treatment for metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma. Opdivo was first approved for use in July 2014, and is now approved in more than 65 countries. Conor Kavanagh. Source link.

Clinical Trials

Drug Target Review

APRIL 3, 2024

This multi-layered mechanism contributes to the development of immunoresistance against current standard-of-care treatments such as checkpoint inhibitors, chemotherapy, or antibody-drug conjugates (ADCs). Visugromab is a monoclonal antibody – a treatment modality that has been extensively studied and de-risked.

Science

The Pharma Data

SEPTEMBER 23, 2020

Avigan has been approved in Japan since 2014 as a treatment for influenza in emergency cases, and generic versions of the therapy are already available. The company said it aims to submit a regulatory filing as early as October, following an additional analysis of the data, with approval possible within a month. Matt Fellows.

Therapies

The Pharma Data

AUGUST 1, 2021

Takeda Pharmaceutical Company Limited today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners’ position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc.

Pharmaceutical Companies

The Pharma Data

DECEMBER 15, 2020

from the Oregon Health & Science University in Portland, and colleagues updated the 2014 HBV screening review in nonpregnant adolescents and adults. Antiviral therapy compared with placebo or no treatment was associated with an increased likelihood of achieving intermediate outcomes based on 18 trials. Roger Chou, M.D., Editorial.

Virus

New Drug Approvals

AUGUST 21, 2023

5] Medical uses Palovarotene is indicated for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. [4] 19] In January 2023, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for palovarotene for the treatment of fibrodysplasia ossificans progressiva. [20]

FDA

New Drug Approvals

SEPTEMBER 13, 2024

2] Like other kappa opioid antagonists currently under clinical investigation for the treatment of major depression, its efficacy may be compromised by the countervailing activation of pro-inflammatory cytokines in microglia within the CNS. [7] 2] Aticaprant is taken by mouth. [1] nM vs. 24.0 13] [14] Occupancy was 35% for a 0.5 nM vs. 24.0

Treatment

The Pharma Data

NOVEMBER 10, 2020

from Harvard Medical School in Boston, and colleagues developed machine learning models to predict antibiotic susceptibility using electronic health record data and built a decision algorithm for recommending the narrowest possible antibiotic to which a specimen is susceptible for the treatment of uncomplicated UTI. Sanjat Kanjilal, M.D.,

Medical Schools